No. As of June 2026, Zepbound is not on the FDA drug shortage list. The tirzepatide shortage was declared resolved on October 2, 2024 and reaffirmed that December, and it has stayed off the list since. But there is a catch the headlines miss: the drug substance is fine, while the injector pens still run tight at some pharmacies, especially the higher maintenance doses. Here is the real, dated availability picture, why vials are easier to get than pens, and what to do if your exact dose is out.
If you keep hitting empty shelves, one reliable workaround is switching to compounded tirzepatide shipped to your door from a licensed telehealth provider, the same active ingredient as Zepbound. The full supply breakdown is below.
Live status check, verified June 2026
Tirzepatide injection (Zepbound and Mounjaro) is NOT listed on the FDA Drug Shortage Database as of June 2026. Supply status can change, so confirm the current entry yourself at the FDA database (search "tirzepatide injection") before assuming your dose is available.
🔑 Key Takeaways
- The shortage is officially over. The FDA resolved the tirzepatide shortage in late 2024 and it has not returned to the list.
- Off the list does not mean every dose is on every shelf. Pharmacy stock still varies by strength and location, day to day.
- Pens are the bottleneck, not the medicine. The active ingredient is in good supply; injector pen manufacturing is the slower piece.
- Vials are the workaround. LillyDirect self-pay single-dose vials are frequently available when pharmacy pens are not.
- Mass compounding is no longer legal. Now that the shortage is resolved, compounded tirzepatide is limited to patient-specific medical need, and the FDA has proposed tightening it further.
Telehealth Comparison Table
When your pharmacy is out of your dose, these are the two telehealth providers our readers use most for compounded tirzepatide, the same molecule as Zepbound, shipped directly.
Is Zepbound in shortage right now?
No, not officially. The FDA first declared the tirzepatide shortage resolved on October 2, 2024. A compounder group sued, the FDA agreed to take another look, and then on December 19, 2024 it reaffirmed the resolution, pointing to Lilly production and inventory data showing supply meets or exceeds demand. Tirzepatide had been on the shortage list since December 15, 2022, so that was the end of a two-year run. It has stayed off the list since.
That official status matters because it controls the rules for compounding, which we cover below. But it does not perfectly match what you may see at your own pharmacy counter.
Off the list, but still choppy at the counter
Here is the honest version. Resolved means the FDA has determined nationwide supply can meet nationwide demand. It does not mean your specific 12.5 mg pen is sitting on the shelf at your local store today. Distribution is uneven, and individual pharmacies still report short gaps on certain strengths.
The reason is subtle. The tirzepatide drug substance itself is not the problem anymore. The slower piece is the injector pen device, the autoinjector that delivers the dose. Pen and KwikPen manufacturing capacity has lagged behind the raw medicine, which is why you can sometimes get a vial when a pen is unavailable.
Zepbound availability by dose in 2026
Patient reports through 2026 suggest availability tracks loosely with dose strength. Treat the table below as directional, gathered from patient and pharmacy reports rather than from the FDA, and always confirm your exact strength with your own pharmacy.
| Dose | Typical availability (reported) | What to do |
|---|---|---|
| 2.5 mg (starter) | Widely available | Usually fillable same day |
| 5 mg, 7.5 mg | Generally good | May take 1 to 3 days to fill |
| 10 mg | Occasional gaps | Call ahead; consider the vial format |
| 12.5 mg, 15 mg (maintenance) | Tightest | Pre-order early; vials or telehealth are good backups |
For real-time, strength-specific stock, Lilly's own supply tool is more reliable than any third-party chart, since it reflects the manufacturer's current view by dose.
Why vials are easier to get than pens
If your pharmacy keeps coming up empty on pens, the single-dose vial is your friend. Lilly fills vials on different capacity than autoinjector pens, and vial supply scaled up faster. Vials are sold through LillyDirect self-pay, and after a December 2025 price cut they run $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg and higher. You draw the dose with a syringe instead of clicking a pen, which is the only real tradeoff. For the full ordering walkthrough, see how to buy Zepbound online.
Is compounded tirzepatide still legal in 2026?
Mostly not, and this is where the resolved shortage changed everything. While a drug is in shortage, pharmacies are allowed to compound copies of it. Once the FDA declared tirzepatide resolved, that window closed on a clear schedule:
- February 18, 2025: state-licensed 503A pharmacies had to stop compounding tirzepatide copies.
- March 19, 2025: larger 503B outsourcing facilities had to stop as well.
Since then, a 503A pharmacy can compound tirzepatide only on a patient-specific basis when a prescriber documents a real clinical reason the FDA-approved product will not work, such as a documented allergy to an inactive ingredient or a medically necessary non-standard strength. Routine mass compounding of copies is no longer allowed. Note that this is stricter than semaglutide, where the FDA kept some discretion.
It may tighten further. On April 30, 2026 the FDA proposed excluding tirzepatide, semaglutide, and liraglutide from the 503B bulks list, finding no clinical need for outsourcing facilities to compound them from bulk. This is a proposal, not a final rule, with a public comment window that runs into late June 2026. If finalized, it would further restrict large-scale compounding. For the current legal picture, see our guide to compounded tirzepatide. Licensed telehealth providers that still offer it generally operate through the patient-specific 503A pathway.
How to check Zepbound availability and set alerts
- Check the FDA Drug Shortage Database. Search "tirzepatide injection" for the official national status.
- Use Lilly's supply tool at supply.lilly.com to see availability by specific strength.
- Call your pharmacy and ask about your exact dose, not just "Zepbound." Stock changes daily, so recheck over several days if needed.
- Ask the pharmacy to order it in or transfer your prescription to a store that has your strength.
- Set refill and price alerts in GoodRx or your pharmacy app so you are notified when stock and pricing move.
- Consider LillyDirect vials or telehealth as a parallel backup so you are never forced to skip a week.
What to do if your dose is out of stock
First rule: do not improvise. Do not split a different strength, double up, or stretch your schedule without talking to your prescriber, since dose accuracy matters and missed weeks can bring back side effects when you restart. Instead:
- Ask your prescriber whether switching to the LillyDirect vial of your dose makes sense while pens are tight.
- Check nearby pharmacies and offer to transfer the prescription.
- If you will be without medication for a stretch, ask about a bridge plan rather than a hard stop, since stopping leads to appetite returning and weight regain over time.
- Compounded tirzepatide through a licensed telehealth provider can keep the same molecule flowing if it fits your situation.
For the bigger picture on results and what to expect, our tirzepatide reviews and what Zepbound is and costs guides go deeper.
Frequently Asked Questions
The bottom line
Zepbound is not in an official shortage in 2026, but availability is still a moving target by dose and location. If your pharmacy is out, the answer is rarely to wait and skip a week. Switch to a vial, transfer the prescription, or bridge with compounded tirzepatide, and keep an eye on the FDA database and Lilly's supply tool for your specific strength. The medicine is here. Getting your exact dose just takes a little strategy.
References
- U.S. FDA. Declaratory Order: Resolution of Shortages of Tirzepatide Injection (December 19, 2024). fda.gov.
- U.S. FDA. FDA Clarifies Policies for Compounders as National GLP-1 Supply Begins to Stabilize (503A and 503B deadlines). fda.gov.
- U.S. FDA. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide From the 503B Bulks List (April 30, 2026). fda.gov.
- U.S. FDA. Drug Shortage Database, tirzepatide injection (live status check). dps.fda.gov.
- BioPharma Dive. Zepbound, Mounjaro shortages are resolved, FDA confirms. biopharmadive.com.
- Wilson Sonsini. FDA Announced Removal of Tirzepatide From the Drug Shortage List. wsgr.com.
- NCPA. FDA Ends Compounding Discretion for Tirzepatide, Maintains Discretion for Semaglutide. ncpa.org.
- PharmExec. Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients (December 1, 2025). pharmexec.com.
- LillyDirect. Authentic Zepbound (tirzepatide), vials and self-pay. lilly.com.
- Eli Lilly. Medicine Supply Information (supply.lilly.com). supply.lilly.com.
